Filing Details

Accession Number:
0001144204-10-002774
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-01-20 12:00:00
Reporting Period:
2010-01-19
Filing Date:
2010-01-20
Accepted Time:
2010-01-20 17:09:11
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1318641 Cleveland Biolabs Inc CBLI Services-Commercial Physical & Biological Research (8731) 200077155
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1370083 V Andrei Gudkov 73 High Street
Buffalo NY 14203
Chief Scientific Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-01-19 400 $3.87 1,529,200 No 4 S Direct
Common Stock Disposition 2010-01-19 500 $3.90 1,528,700 No 4 S Direct
Common Stock Disposition 2010-01-19 300 $3.91 1,528,400 No 4 S Direct
Common Stock Disposition 2010-01-19 189 $3.86 1,528,211 No 4 S Direct
Common Stock Disposition 2010-01-19 1,500 $3.88 1,526,711 No 4 S Direct
Common Stock Disposition 2010-01-19 1,411 $3.89 1,525,300 No 4 S Direct
Common Stock Disposition 2010-01-19 700 $3.85 1,524,600 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Employee Stock Options (Right to Buy) $8.36 2007-04-06 2017-04-05 37,500 37,500 Direct
Common Stock Employee Stock Options (Right to Buy) $4.00 2008-02-04 2018-02-03 137,250 174,750 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2017-04-05 37,500 37,500 Direct
2018-02-03 137,250 174,750 Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.